Signs of Oxycodone Use Disorder
Oxycodone use disorder is a medical condition, not a character flaw. For patients who started on a prescription — which is most oxycodone patients we see — it often isn’t loud. The prescription-opioid version of dependence frequently looks like a functional adult holding things together while the pills quietly run the background math. Common signs include:
- Tolerance and dose escalation. The dose that worked when it was first prescribed doesn’t anymore. What started as one 10 mg OxyContin every 12 hours becomes two. What was two 5 mg Roxicodone tablets becomes three or four. The total daily amount has crept well above what was originally prescribed, often without a corresponding increase in pain relief.
- Running out early. The 30-day prescription lasts 22 days. Then 18. Then 14. A pattern of “lost” bottles, “stolen” prescriptions, or early refill requests is one of the clearest clinical signals, and one of the reasons the Tennessee CSMD was built.
- Breaking, crushing, or chewing ER pills. Extended-release OxyContin was designed to be taken whole. Breaking, crushing, or chewing ER pills defeats the release mechanism and delivers the full 12-hour dose at once. Doing this, or looking for pre-reformulation (“OC”) pills versus post-2010 (“OP”) pills, is a marker of both escalating misuse and physical dependence.
- Doctor-shopping or multi-sourcing. Visiting more than one provider to keep supply steady — a family doctor, a pain clinic, urgent care, a dentist, the ER. The Tennessee CSMD now requires providers to check prescription history before writing Schedule II opioids, which makes this pattern far easier to catch than it was a decade ago.
- Switching to cheaper or stronger alternatives. When the prescription access closes — a tapering pain plan, a provider retirement, an insurance change — patients commonly switch to illicit “30s” or “Roxies” off the street, to heroin, or increasingly (and usually unknowingly) to fentanyl-pressed counterfeit oxycodone. Many of our patients never imagined they’d buy drugs from someone outside a pharmacy and then did, because the alternative was withdrawal.
- Withdrawal fear driving the next dose. Taking the pill not for pain, not for euphoria, but to keep sickness away. The morning dose before work. The extra pill before a holiday gathering because you know what 12 hours without one feels like. Life getting scheduled around the dose clock.
- Loss of control. Deciding you’ll only take the prescribed dose today and not being able to. Making and breaking the same “this is the last bottle” promise to yourself, a spouse, or an adult child for months or years.
- Hiding use. Taking pills where no one sees. Lying about how many are left. Stashing a reserve supply. Family members often spot the behavior around the pills before the pills themselves.
- Continued use despite consequences. Using even when it’s costing you — financially, professionally, medically, legally, relationally. Continued use in the face of mounting consequences is one of the DSM-5 criteria for opioid use disorder.
You do not have to meet every item on this list. The formal DSM-5 threshold for opioid use disorder is 2 of 11 criteria in a 12-month period. Mild, moderate, and severe are all treatable — and earlier is almost always easier than later.
Oxycodone Withdrawal: Timeline and Symptoms
Oxycodone withdrawal is uncomfortable. For most healthy adults it is not life-threatening the way alcohol or benzodiazepine withdrawal can be, but it is severe enough that many patients relapse just to make it stop. That is not weakness — it is physiology, and medication-assisted treatment is designed specifically to prevent it rather than force you to push through.
Oxycodone’s pharmacokinetics depend on the formulation. Immediate-release oxycodone (Roxicodone, Oxaydo, generic IR) has a half-life of roughly 3 to 4.5 hours; extended-release OxyContin has a functional half-life closer to 4.5 to 5.5 hours with a much flatter blood-level curve. That distinction shapes the timeline you’ll actually experience:
- First 8 to 24 hours after last dose. Early symptoms begin: anxiety, restlessness, irritability, muscle aches, yawning, watery eyes, runny nose, sweating, and cravings. Sleep becomes difficult the first night. For immediate-release oxycodone the onset tends to be earlier (8–12 hours). For extended-release OxyContin it often takes 12–24 hours because blood levels were smoother going in.
- Day 1 to day 3 (peak). Full picture: nausea, vomiting, diarrhea, abdominal cramping, chills alternating with sweating, dilated pupils, goosebumps (“kicking”), muscle and bone aches, profound fatigue, and intense cravings. Heart rate and blood pressure rise. Insomnia persists. This is the window in which unmedicated quit attempts almost always fail.
- Day 3 to day 7. Acute GI symptoms gradually subside. Appetite may start to return. Sleep is still fragmented. Cravings remain strong. Low mood and anxiety often peak here as the nervous system re-regulates.
- Week 2 and beyond (post-acute withdrawal). Low energy, difficulty concentrating, mood changes, anhedonia, and intermittent cravings can last weeks to several months. For long-term prescribed ER oxycodone patients, this phase is often described as more diffuse and more protracted than short-term IR use — the nervous system is re-calibrating after years of smooth, steady opioid exposure. That is not a sign that treatment isn’t working. It is the body relearning. MAT dramatically shortens and softens this phase.
Two clinical considerations matter specifically for oxycodone patients:
- Long-term prescribed ER oxycodone. Patients who have been stable on OxyContin at a prescribed dose for years often have the most protracted post-acute course and the highest relapse risk during the acute window. They’re also the patients most likely to need coordinated pain management planning alongside MAT. Buprenorphine-based treatment is particularly well-suited to this population because buprenorphine is itself a potent analgesic.
- Counterfeit-pill fentanyl exposure. If the “oxycodone” you’ve been taking came from anywhere other than a pharmacy — street pills stamped M30, K9, or other oxycodone markings — fentanyl exposure should be assumed. Fentanyl clears more slowly than real oxycodone because it stores in body fat, which means the induction window for starting buprenorphine shifts longer, typically 36 to 72 hours rather than 8 to 24. Your provider measures COWS at intake to time induction correctly.
How We Treat Oxycodone Addiction
At Restoration Recovery, oxycodone use disorder is treated with a combination of medication and psychosocial support. Every opioid patient is evaluated for medication-assisted treatment because the evidence supporting MAT is overwhelming — more than a 50% reduction in fatal overdose risk, significantly longer retention in treatment, and sharply lower rates of illicit opioid use. The medication options available to you are:
- Suboxone (daily film or tablet). A combination of buprenorphine and naloxone taken sublingually — a dissolving film or tablet placed under the tongue. Buprenorphine is a partial opioid agonist: it stabilizes cravings and prevents withdrawal at the same opioid receptors oxycodone was acting on, but with a ceiling effect on euphoria and respiratory depression. For many prescription-first patients, same-day Suboxone induction is clinically appropriate and dramatically easier than a cold-turkey attempt. The naloxone component is inactive when the medication is taken correctly; it’s included to discourage injection misuse.
- Sublocade (monthly injection). A long-acting extended-release form of buprenorphine administered once per month at our clinics. Many patients transition from Suboxone to Sublocade because it removes the daily decision-making around taking medication, holds steadier blood levels throughout the month, and — importantly for patients whose dependence began with pill-taking — removes the pill ritual entirely. Per FDA labeling, Sublocade requires at least 7 days of transmucosal buprenorphine (Suboxone) before the first injection.
- Brixadi (weekly, bi-weekly, or monthly injection). Another extended-release buprenorphine injection with flexible dosing intervals. Brixadi’s weekly and bi-weekly options can be helpful for patients still finding the right maintenance dose or who prefer a shorter interval than Sublocade’s monthly cadence. Like Sublocade, Brixadi is ordered per-patient and administered at a follow-up visit once the medication arrives.
Medication alone is effective, but medication paired with behavioral support is more effective. We pair MAT with:
- Individual counseling with licensed therapists experienced in substance use disorder. Counseling for prescription-opioid patients often surfaces material specific to this pathway — the original pain event or injury, the relationship with the original prescribing provider, the shame of needing medication to function, the long arc of hidden use within a family.
- Certified peer support from specialists who have lived experience with recovery themselves. Many of our peer specialists walked the same OxyContin-to-heroin-to-recovery arc our patients are walking, and that conversation sometimes opens what a clinical conversation cannot.
- Intensive outpatient programming (IOP) for patients who benefit from a more structured treatment schedule — delivered in a group format by design. IOP is the only group-setting service we offer, and it’s a separate, structured program rather than an informal group activity.
- Integrated care for co-occurring conditions, including anxiety, depression, trauma, chronic pain, and hepatitis C. Hepatitis C in particular rose sharply after the 2010 OxyContin reformulation as patients transitioned to injection heroin use; for patients with that history, we treat it in-house rather than refer it out.
Restoration Recovery is an outpatient clinic. We do not provide medical detox or residential care. For most patients with oxycodone use disorder, a formal inpatient detox is not required — MAT can begin at the appropriate COWS-score window after last use, under clinical supervision. For patients who need a higher level of care before starting outpatient MAT, we coordinate with regional referral partners.
Chronic Pain & OxyContin Transition Planning
A meaningful share of our oxycodone patients arrive with an active chronic pain history — many on long-term prescribed OxyContin, Roxicodone, or generic oxycodone for conditions that are still real and still painful. Starting MAT does not mean abandoning pain management. Buprenorphine — the active medication in Suboxone, Sublocade, and Brixadi — is itself a potent analgesic. As a partial opioid agonist it provides real, measurable pain relief, and plenty of our patients report their pain is better controlled on buprenorphine than on escalating oxycodone, largely because their nervous system stops cycling through mini-withdrawal between doses.
When a patient has an active pain management relationship with another provider, we coordinate rather than compete. The goal is one consistent plan between us, the pain provider, and the patient — not two parallel medication lists that contradict each other. If you’ve been told you have to choose between recovery and pain management, that isn’t the clinical reality. It’s a conversation worth having at intake.
What to Expect at Your First Appointment
Your first visit typically lasts 60 to 120 minutes and follows a four-step clinical flow:
- Intake. You’ll complete paperwork and a clinical intake. For opioid use disorder, this includes a DSM-5 assessment to confirm the diagnosis and its severity (mild, moderate, or severe based on how many of the 11 criteria you meet in a 12-month period), and a COWS (Clinical Opiate Withdrawal Scale) score to measure your current withdrawal state. The COWS score guides whether you’re clinically ready to begin buprenorphine the same day without risking precipitated withdrawal.
- Counseling. You’ll meet with a counselor to discuss your substance use history — including the original prescription pathway if that’s how your use started — any previous treatment, any co-occurring mental health conditions, and your personal recovery goals. This is also where any active pain management relationship or OxyContin taper history gets documented.
- Doctor evaluation. A medical provider reviews your intake, COWS score, and counselor notes. They walk you through the medication options (Suboxone, Sublocade, Brixadi), explain onset, side effects, and timing, and answer your questions. For patients with long-term prescribed OxyContin or Roxicodone histories, this is also where transition planning — including any coordination with a pain provider — gets mapped out.
- Prescription (and injection ordering, if chosen). If clinically appropriate, you leave the same day with a Suboxone prescription. If you prefer the extended-release route, your provider will order Sublocade or Brixadi during this visit — we don’t stock injections on-site — and you’ll continue on Suboxone as a bridge. Your injection appointment is scheduled for a follow-up once the medication arrives, typically after a short stabilization period on Suboxone (Sublocade’s FDA label requires at least 7 days of transmucosal buprenorphine before the first injection).
Bring a valid photo ID, your insurance card if applicable, and a list of any medications you currently take (including the specific oxycodone product, dose, the original prescribing reason, and any pain medications or benzodiazepines). If you’d like to see the full process walked through step by step before your visit, our guide on what to expect at your first Suboxone appointment covers it in more detail.
Why Medication-Assisted Treatment Works for Oxycodone
For many patients, the fear of withdrawal is what keeps them stuck. MAT removes that barrier — the medication prevents withdrawal rather than forcing patients to endure it — which is why it works when willpower alone doesn’t.
Medication-assisted treatment is endorsed as the standard of care for opioid use disorder, including prescription opioid use disorder specifically, by the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA), the American Society of Addiction Medicine (ASAM), and the World Health Organization. Buprenorphine was actually most extensively studied, prior to the illicit-fentanyl era, in prescription opioid populations — trials like COMBINE and POATS enrolled patients whose dependence began with pills. For oxycodone patients in particular, the evidence base is deep.
Large-scale evidence shows that patients with opioid use disorder who receive buprenorphine-based MAT:
- Experience more than a 50 percent reduction in the risk of fatal opioid overdose
- Stay in treatment significantly longer than those receiving counseling alone
- Report fewer cravings and lower rates of illicit opioid use
- Are more likely to maintain employment and stable housing during recovery
- Have lower rates of infectious disease transmission associated with injection use
There’s a clinical advantage specific to oxycodone patients that’s worth naming. Because oxycodone is shorter-acting and clears more predictably than fentanyl, buprenorphine induction is typically smoother for oxycodone-first patients than for long-term fentanyl patients. The COWS window is more reliable (8–24 hours after last immediate-release dose, somewhat longer for OxyContin), the transition onto steady-state buprenorphine is usually faster, and most patients describe the subjective experience of the first medicated day as relief within hours rather than the rougher, longer induction that long fentanyl histories sometimes require. For patients who have been quietly dreading this step for months or years, that is often the most surprising part of day one.
MAT is not a replacement of one drug with another. Buprenorphine’s partial-agonist pharmacology gives it a ceiling effect on euphoria and respiratory depression that full agonists like oxycodone, hydrocodone, and fentanyl don’t have. Blood levels stabilize, the daily cycle of peak-and-crash disappears, and the neurological noise that drove continued use recedes. Patients can engage in counseling, rebuild relationships, and return to work without the daily math of craving, dosing, running out, and withdrawing.
Why Restoration Recovery
Choosing where to start treatment matters. Restoration Recovery brings together the clinical depth, the practical access, and the kind of care that keeps patients in treatment long enough to get well.
- Chattanooga’s longest-running outpatient addiction treatment clinic. Our providers have decades of clinical experience treating opioid and substance use disorders in Southeast Tennessee — through the full arc of the OxyContin era, the pill-mill years, the 2010 reformulation, the heroin transition, and the fentanyl contamination of the pill supply that followed. We’ve treated every version of this clinical picture.
- CARF accredited. The Commission on Accreditation of Rehabilitation Facilities is the gold standard for outpatient addiction care — our accreditation is reviewed on an ongoing basis, not a one-time stamp.
- Four clinic locations across Southeast Tennessee and North Georgia, with telehealth follow-up available for established patients.
- Most major insurance accepted — TennCare, Georgia Medicaid, commercial plans, Medicare, and supplemental Medicare. Our patient services team verifies your benefits before your first visit so there are no surprises.
- Same-day Suboxone appointments in most cases. You don’t have to wait weeks to start.
- One integrated team. Medical providers, counselors, certified peer support specialists, and psychiatric care under one roof — not parallel referral tracks that leave you coordinating your own care. For patients with co-occurring chronic pain, anxiety, depression, or hepatitis C, this matters.
- Licensed in both states. Licensed in Tennessee and Georgia, HIPAA compliant, 42 CFR Part 2 compliant — your treatment is confidential from the first phone call.
Insurance and Access
Restoration Recovery accepts most major insurance plans, including TennCare, Georgia Medicaid, a broad range of commercial plans, and Medicare (plus supplemental Medicare plans). Our patient services team can verify your benefits before your first appointment so you know exactly what to expect in terms of cost.
If you do not have insurance, contact us anyway. We can help you explore options and will walk you through self-pay pricing. For a full list of accepted carriers and details on the verification process, visit our insurance page.
Four Clinic Locations
We operate four outpatient clinics across Southeast Tennessee and North Georgia. All locations offer oxycodone addiction treatment with same-day appointments in most cases:
- Chattanooga, TN — 6141 Shallowford Rd, Suite 100, Chattanooga, TN 37421
- Cleveland, TN — Serving Bradley County and surrounding areas
- Soddy-Daisy, TN — Serving Hamilton County north and the Sequatchie Valley
- Ringgold, GA — Serving Catoosa County and Northwest Georgia
Telehealth follow-up visits are available for established patients who have completed their initial in-person evaluation. For directions, hours, and contact information, visit our locations page.
Frequently Asked Questions
What if I’ve been prescribed oxycodone for years?
Long-term prescribed oxycodone patients are a large share of our opioid caseload. If you’ve been taking OxyContin, Roxicodone, or generic oxycodone on a prescription for years and you’ve developed physical dependence — or your supply has been disrupted by a tapering pain plan, a provider retirement, or a change in how your insurance covers Schedule II opioids — you qualify for MAT. You don’t have to be using illicitly to be eligible. The right move is not to stop on your own; it’s to come in, be evaluated with a DSM-5 and COWS, and build a transition plan with your provider that may include coordination with whoever is managing your pain.
Is OxyContin withdrawal different from immediate-release oxycodone withdrawal?
The timeline shifts. Immediate-release oxycodone (Roxicodone, Oxaydo, generic oxycodone IR) has a shorter half-life, so withdrawal typically begins 8–12 hours after the last dose and peaks hard at day 1–3. Extended-release OxyContin produces a more gradual onset — often 12–24 hours — and many patients describe the post-acute phase as more diffuse and more protracted, because blood levels were smoother going in and the nervous system was re-calibrating from a steadier exposure. Both resolve on a similar day 5–7 curve for acute symptoms, and MAT with buprenorphine prevents the acute phase rather than forcing you to endure it.
What about fake oxycodone pills — I was buying “30s” outside a pharmacy?
Assume they contained fentanyl. The illicit “oxycodone 30” (M30) pill supply in the U.S. is now dominated by counterfeit pressings containing fentanyl rather than oxycodone. If you’ve been buying pills stamped M30, K9, or other oxycodone markings from anyone outside a pharmacy — for months or years — fentanyl exposure should be assumed, regardless of what you thought you were taking. This doesn’t change the MAT plan; it does change the induction timing, because fentanyl clears more slowly than real oxycodone. Your provider will calibrate at intake based on your COWS score and use history.
Do I have to stop oxycodone cold turkey before my first visit?
No. You shouldn’t stop on your own, and you don’t need to be in full-blown withdrawal when you call. For oxycodone, the target induction window is typically 8–24 hours after the last immediate-release dose, longer for OxyContin, and longer still for patients with mixed fentanyl exposure from counterfeit pills. The COWS assessment at your first visit tells the provider whether you’re clinically ready to start buprenorphine the same day without risking precipitated withdrawal. Keep taking your current dose until your appointment — your provider will guide the exact timing at intake.
Can MAT replace my chronic pain medication?
For many patients, yes — and sometimes the pain control on buprenorphine is better than it was on escalating oxycodone. Buprenorphine is itself a potent analgesic — it partially activates the same opioid receptors as oxycodone without the euphoria, the same overdose risk, or the daily peak-and-crash cycle. Many chronic-pain patients find their pain is better controlled on buprenorphine than on higher oxycodone doses, because their nervous system is no longer cycling through mini-withdrawal between doses. For patients with an active pain management relationship, we coordinate rather than compete — the goal is one consistent plan, not two parallel medication lists. If you’ve been told you have to choose between recovery and pain relief, that isn’t the clinical reality.
How is buprenorphine induction different for oxycodone vs fentanyl dependence?
Typically smoother. Oxycodone is shorter-acting and clears more predictably than fentanyl, which stores in body fat and can linger in the system for days after last use. For oxycodone-first patients, the COWS induction window is usually 8–24 hours after last dose, the transition onto steady-state buprenorphine is typically faster, and the subjective experience of starting treatment is more often described as relief within hours. For patients who have also been exposed to fentanyl through counterfeit M30 pills, the window shifts longer — typically 36–72 hours — and your provider calibrates at intake to avoid precipitated withdrawal. Both paths lead to the same place; the timing just differs.
Take the Next Step
Oxycodone addiction is survivable, and treatment works — whether your use started with an OxyContin prescription in 2003 for back pain that never quite resolved, a Roxicodone script after surgery, or somewhere messier than either. You don’t have to figure this out alone, you don’t need to have all the answers before you call, and you don’t need to be clean before your first appointment. Our team will walk you through the process from your first phone call to your first visit and every follow-up after that.
Same-day appointments are available in most cases. Contact us today to schedule your evaluation, or call 423-498-2000 to speak with our team directly.
